{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:31:35Z","timestamp":1794267095107,"version":"4.9.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Nederland Ministerie van Volksgezondheid Welzijn en Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.vaccine.2022.01.013","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:35:17Z","timestamp":1642379717000},"page":"970-976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["COVID-19 vaccine reactogenicity \u2013 A cohort event monitoring study in the Netherlands using patient reported outcomes"],"prefix":"10.1016","volume":"40","author":[{"given":"Le\u00e0n","family":"Rolfes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"H\u00e4rmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leontine","family":"van Balveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wil","family":"Hilgersom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"van Hunsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.01.013_b0005","unstructured":"European Medicines Agency EMA. SmPC Comirnaty; 2021 [updated 12-07-2021]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/comirnaty-epar-product-information_en.pdf."},{"key":"10.1016\/j.vaccine.2022.01.013_b0010","unstructured":"European Medicines Agency EMA. SmPC Spikevax; 2021 [updated 12-07-2021]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf."},{"key":"10.1016\/j.vaccine.2022.01.013_b0015","unstructured":"European Medicines Agency EMA. SmPC Vaxzevria; 2021 [updated 2021]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf."},{"key":"10.1016\/j.vaccine.2022.01.013_b0020","unstructured":"European Medicines Agency EMA. SmPC Covid-19 vaccine Janssen; 2021 [updated 07-07-2021]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/covid-19-vaccine-janssen-epar-product-information_en.pdf."},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.013_b0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"issue":"27","key":"10.1016\/j.vaccine.2022.01.013_b0030","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"issue":"10277","key":"10.1016\/j.vaccine.2022.01.013_b0035","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.vaccine.2022.01.013_b0040","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.vaccine.2015.03.014","article-title":"Web-based intensive monitoring of adverse events following influenza vaccination in general practice","volume":"33","author":"van Balveren-Slingerland","year":"2015","journal-title":"Vaccine."},{"issue":"10","key":"10.1016\/j.vaccine.2022.01.013_b0045","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.vaccine.2010.12.123","article-title":"Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring","volume":"29","author":"H\u00e4rmark","year":"2011","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2022.01.013_b0050","unstructured":"BijwerkingencentrumLareb. Mijn Coronavaccin; 2021 [updated 2021]. Available from: https:\/\/mijncoronavaccin.nl\/."},{"key":"10.1016\/j.vaccine.2022.01.013_b0055","unstructured":"European Medicines Agency EMA. Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 4); 2017. https:\/\/wwwemaeuropaeu\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_enpdf."},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.013_b0060","article-title":"The how's and what's of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vacc"},{"key":"10.1016\/j.vaccine.2022.01.013_b0065","unstructured":"Kleijne I. Veel huisartsen grieperig na Moderna-inentingen. Medisch Contact; 2021 [15-03-2021]."},{"key":"10.1016\/j.vaccine.2022.01.013_b0070","unstructured":"Rijksoverheid. 2021 Vaccinatieplanning [updated 2021]. Available from: https:\/\/www.rijksoverheid.nl\/onderwerpen\/coronavirus-vaccinatie\/volgorde-van-vaccinatie-tegen-het-coronavirus."},{"issue":"3","key":"10.1016\/j.vaccine.2022.01.013_b0075","first-page":"249","article-title":"Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey","volume":"11","author":"Mathioudakis","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.vaccine.2022.01.013_b0080","unstructured":"The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Welcome to MedDRA; 2021 [updated 2017\/06\/16\/]. Available from: https:\/\/www.meddra.org\/."},{"key":"10.1016\/j.vaccine.2022.01.013_b0085","first-page":"650","article-title":"Vaxbatch: A stratified disproportionality analysis tool for batch-related AEFI monitoring in vaccines","author":"Scholl","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2022.01.013_b0090","unstructured":"Norwegian Institute of Public. ATC Structure and principles; 2011 [updated 2017\/06\/01\/]. Available from: https:\/\/www.whocc.no\/atc\/structure_and_principles\/."},{"issue":"10267","key":"10.1016\/j.vaccine.2022.01.013_b0095","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vaccine.2022.01.013_b0100","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect Dis."},{"issue":"21","key":"10.1016\/j.vaccine.2022.01.013_b0105","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.2021.5374","article-title":"Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines","volume":"325","author":"Chapin-Bardales","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.013_b0110","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/vaccines9050522","article-title":"The Gender Impact Assessment among Healthcare Workers in the SARS-CoV-2 Vaccination-An Analysis of Serological Response and Side Effects","volume":"9","author":"Di Resta","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.vaccine.2022.01.013_b0115","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/vaccines9070685","article-title":"Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI","volume":"9","author":"Pellini","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.01.013_b0120","doi-asserted-by":"crossref","first-page":"100928","DOI":"10.1016\/j.eclinm.2021.100928","article-title":"Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine","volume":"36","author":"Pellini","year":"2021","journal-title":"EClinicalMedicine."},{"issue":"8","key":"10.1016\/j.vaccine.2022.01.013_b0125","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1007\/s11695-021-05404-y","article-title":"COVID-19 Vaccines: Special Considerations for the Obese Population","volume":"31","author":"Kipshidze","year":"2021","journal-title":"Obes Surg."},{"key":"10.1016\/j.vaccine.2022.01.013_b0130","unstructured":"Harmark L. Web-based Intensive Monitoring; a patient based pharmacovigilance tool: Rijksuniversiteit Groningen; 2012."},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.013_b0135","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/pds.5175","article-title":"Inflammatory bowel disease patients provide reliable self-reported medical information: A multicentre prospective pharmacovigilance monitoring system","volume":"30","author":"Thomas","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.013_b0140","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/kez412","article-title":"Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system","volume":"59","author":"Kosse","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vaccine.2022.01.013_b0145","unstructured":"RIVM. Vaccinatieregistratie bij het RIVM en uw privacy; 2021 [updated 2021]. Available from: https:\/\/www.rivm.nl\/covid-19-vaccinatie\/privacy."},{"key":"10.1016\/j.vaccine.2022.01.013_b0150","unstructured":"RTL Nieuws. Tijdlijn: hoe Nederland te laat het testen op corona uitbreidde; 2021 [updated 21-08-2020]. Available from: https:\/\/www.rtlnieuws.nl\/nieuws\/artikel\/5136981\/reconstructie-testen-traceren-corona."},{"key":"10.1016\/j.vaccine.2022.01.013_b0155","unstructured":"Cohort Event Monitoring of safety of COVID-19 vaccines (Early-Covid-Vaccine-Monitor) [Internet]; 2021 [cited 14-07-2021]. Available from: http:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=40288."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:08:52Z","timestamp":1759403332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22000287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0264410X22000287"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccine reactogenicity \u2013 A cohort event monitoring study in the Netherlands using patient reported outcomes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}